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ABSTRACT
Introduction. Neopterin is a byproduct of nerve trans-
mitter coenzyme that is synthesized and released by 
macrophages and T-lymphocytes. It is a useful inflam-
matory marker of diabetes progression, as its levels 
increase with the progression of the disease from 
prediabetes to type 2 diabetes (T2D). This study aimed 
to compare serum neopterin levels between type-1 and 
type-2 diabetes patients with diabetic foot syndrome 
(DFS), and assess the relation between serum neopterin 
levels and cardiometabolic risk factors. 
Materials and methods. This observational cross-sec-
tional study was carried out in the Centre of Diabetes 
Mellitus in Erbil, Iraq from 1st January to 31st December 
2016. A total of 30 healthy subjects and 140 patients 
with DFS [70 patients with type 1 diabetes (T1D) and 
70 patients with T2D] were enrolled in the study. The 
main outcome measurements included anthropometric 
measurements, blood pressure, fasting serum glucose, 
glycated haemoglobin, lipid profile, neopterin and high 
sensitivity C-reactive protein (hs-CRP). 
Results. Serum neopterin levels of T2D patients were 
significantly (p < 0.001) higher than the corresponding 
levels of T1D patients (18.6 ± 2.1 nmol/L vs. 12.6 ± 
1.3 nmol/L). The changes in the serum neopterin levels 
were related to cardiometabolic risk factors. In T1D, 
a significant positive correlation between serum levels 
of neopterin and diastolic blood pressure were ob-
served, while in T2D the significant positive correlation 
was found between fasting serum triglyceride levels 
and neopterin levels. Serum levels of neopterin were 
insignificantly correlated with hs-CRP in T1D and T2D. 
Conclusions. In patients with DFS, serum neopterin lev-
els are significantly higher in those with T2D compared 
with T1D patients. Neopterin levels are not related to 
the grading of DFS, but are invariably related to cardio-
metabolic risk factors. (Clin Diabetol 2018; 7, 2: 91–96)
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Introduction
World Health Organization (WHO) defined the 
diabetic foot syndrome (DFS) as ulceration of the foot 
(distally from the ankle and including the ankle) associ-
ated with neuropathy and different grades of ischaemia 
and infection [1]. Previous studies reported that DFS is 
a common complication of diabetes and the prevalence 
up to 27% of diabetic patients was found [2–4]. Lauter-
bach et al. analysed the data of 34,198 patients with 
type 2 diabetes (T2D) and 2,576 patients with type 1 
diabetes (T1D) in the United Kingdom and found that 
DFS prevalence was 7.6% and 8.5%, respectively [5]. 
The results of one study showed that in patients with 
T2D complicated by DFS the inflammatory markers, 
including high sensitivity C-reactive protein, tumour 
necrosis factor-a (TNF-a) and interleukin-6, were sig-
nificantly correlated with cardiometabolic risk factors, 
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including body mass index (BMI), serum triglycerides 
and low density lipoprotein [6]. Poor glycaemic control 
has been associated with wound infection caused by 
multidrug resistant microorganisms [7]. Neopterin is a 
byproduct of nerve transmitter coenzyme that is synthe-
sized and released by macrophages and T-lymphocytes 
[8]. One study found that neopterin was a useful in-
flammatory marker in evaluating the progression of 
diabetes, as its levels increased from prediabetes to T2D 
[9]. Rao et al. (2010) reported a significant increase in 
neopterin serum levels in patients with metabolic syn-
drome (2.142 ± 0.038 nmol/L) compared with subjects 
without metabolic syndrome (2.020 ± 0.044 nmol/L) 
[10]. In gestational diabetes, serum neopterin level is 
increased, but does not significantly correlate with 
high-sensitivity C-reactive protein, which is a marker 
of inflammation [11]. There is evidence suggesting 
that the serum level of neopterin is a predictor of fatal 
ischaemic heart disease in T2D [12]. 
The rationale behind this study was the role of 
cardiometabolic risk factors in the aetiopathogenesis of 
the infection/inflammation in DFS, which may explain 
the differences in serum neopterin levels between pa-
tients with different types of diabetes complicated by 
DFS. This study aimed to assess the serum neopterin 
levels in patients with T1D and T2D complicated by 
DFS and to relate these levels to cardio-metabolic risk 
factors taking into considerations the DFS severity.
Materials and methods
This cross-sectional observational study was carried 
out in the Centre of Diabetes Mellitus in Erbil from 1st 
January to 31st December 2016. The study was con-
ducted according to the guidelines of the Declaration 
of Helsinki with approval of the local ethical review 
board. Informed consent was obtained from each pa-
tient before enrolment into the study. The patients were 
recruited from the Centre of Diabetes Mellitus, and they 
were allocated randomly using randomization tables. 
The criteria of inclusion were: type 1 and 2 diabetes 
(T1D and T2D) complicated by DFS in patients treated 
with oral hypoglycaemic agents and/or insulin, accord-
ing to the clinical status of the patient. The diabetic 
foot syndrome is a clinical condition characterized by 
the presence of ulceration, signs of inflammation and 
infection in the presence or absence of gangrene. The 
Wagner-Meggitt classification was used for grading 
DFS [13]. We used this classification because it is simple 
and provides information related to the objective of the 
study. In addition, our patients were known cases of 
DFS and some of them had a history of amputation; 
therefore, the application of other classifications did 
not offer more advantages. 
The Wagner-Meggitt classification system has six 
grades (0–5) of lesions. The first four grades are based on 
the physical depth of the lesion and the last two grades 
are based on the extent of gangrene. The consultant 
endocrinologist at the diabetes centre performed clini-
cal examination and classified diabetic foot lesions. The 
X-ray as well as specimen culture and sensitivity assessment 
were done for each patient. The presence of diabetic 
peripheral neuropathy was determined on the basis of 
subjective and objective symptoms (pain, numbness, 
vibration, tactile and temperature sensations, pin prick 
and ankle reflex) using the scoring of 0 = absent and 
1 = reduced or present. In those with positive clinical 
evidence of neuropathy electromyography and nerve 
conduction studies (including ulnar, sural and common 
peroneal nerves) were performed to confirm the pres-
ence of peripheral neuropathy. 
Patients with a history of rheumatic, haemato-
logical, neoplastic, renal, liver or thyroid diseases, and 
patients receiving treatment with anti-inflammatory 
drugs were excluded from the study. 
The patients were divided into 3 groups:
 — Group I (n = 30): Apparently healthy control subjects;
 — Group II (n = 70): T1D patients presented with FDS;
 — Group III (n = 70): T2D patients presented with FDS.
Demographic data, medical history and treatment 
information were collected in the centre. Modifiable risk 
factors, events or complications, and current therapy 
were recorded. A person who reported smoking on 
admission was defined as current smoker. Height, 
weight, and waist circumference were measured, and 
body mass index (BMI) was calculated using Quetlete’s 
equation: 
body mass index [kg/m2] = weight [kg]/height2 [m]
Blood pressure was measured in sitting position 
and the mean of three readings was taken. 
The measurements of blood pressure in the dorsalis 
pedis and tibialis posterior arteries were not included 
in the study because a considerable percentage of pa-
tients had a history of amputation, which could be a 
source of bias in the interpretation of the data. Periph-
eral venous blood was drawn into tubes immediately 
after admission. Then the samples were centrifuged at 
2500 rpm for 10 min and the sera were separated for 
determination of fasting serum glucose, HbA1c (%) and 
lipid profile. The lipid profile included fasting serum 
triglycerides and high density lipoprotein-cholesterol. 
Quantitative determination of serum high-sensitivity 
C-reactive protein (hs-CRP) (mg/L) and neopterin were 
carried out using the enzyme-linked immunosorbent 
assay (ELISA) technique. 
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Statistical analysis
Data are expressed as number, percent, and means 
± SD. Unpaired Student’s t-test, and differences be-
tween percentages were used to evaluate differences 
between the two groups and a simple (Pearson’s) corre-
lation test was used to detect the correlations between 
the neopterin and other factors related to DFS. For all 
tests, a two-tailed p ≤ 0.05 was considered statistically 
significant. All calculations were made using Excel 2003 
program for Windows.
Results
Table 1 shows that there is an insignificant dif-
ference between Group II and Group III patients in 
demographic characteristics. Twenty-three (32.9%) 
patients in Group II had a history of toes or foot am-
putation compared with thirty-five (50%) patients in 
Group III; the difference reached the level of statistical 
significance (p = 0.04). Regarding the grading of DFS 
at the time of the current study, significantly (p = 0.05) 
higher number of Group II patients had Grade 2 DFS 
compared with Group III (Tab. 1). Tables 2 and 3 showed 
no statistically significant difference in cardiometabolic 
risk factors or hs-CRP levels depending on the grades of 
DFS in patients with T1D and T2D. Serum levels of hs-
CRP of Group III patients were significantly (p = 0.000) 
higher than the corresponding levels of Group II pa-
tients (12.5 ± 2.6 mg/L vs. 5.7 ± 0.9 mg/L). Serum levels 
of neopterin in Group III patients were significantly 
(p = 0.000) higher than the corresponding levels in Group II 
Table 1. Characteristics of the participants of the study
Characteristics Group I (n = 30) Group II (n = 70) Group III (n = 70)
Gender (male:female) 17:13 54:16 50:20
Age (years) 52 (44–63) 50.5 (43–59) 64.5 (53–72)
Residency (urban:rural) 36:34 29:41
Duration of diabetes (years) – 14 (8–23) 9 (4–20)
Duration of diabetic foot syndrome (months) – 36 24
Previous history of amputation – 23 35*
Grading of diabetic foot syndrome
Grade 1 – 0 0
Grade 2 – 23 13**
Grade 3 – 25 24
Grade 4 – 14 22
Grade 5 – 08 11
The results are expressed as number and median (range). *p = 0.04,** p = 0.05 compared with Group II. Group I: Healthy subjects, Group II: Type 1 diabe-
tes with diabetic foot syndrome, Group III: Type 2 diabetes with diabetic foot syndrome
Table 2. Results of cardiometabolic risk factors, inflammatory marker and neopterin levels according to the grading of 
diabetic foot syndrome in Group II patients
Parameters Grading of diabetic foot syndrome
Grade 2 
(n = 23)
Grade 3 
(n = 25)
Grade 4 
(n = 14)
Grade 5 
(n = 8)
Body mass index [kg/m2] 33.5 ± 2.2 34.9 ± 3.1 34.4 ± 2.9 36.2 ± 3.4
Waist circumference [cm] 85.6 ± 6.1 87.3 ± 5.2 88.3 ± 5.0 90.8 ± 4.0
Systolic blood pressure [mm Hg] 130.6 ± 3.6 131.9 ± 3.7 131.0 ± 3.7 130.1 ± 2.5
Diastolic blood pressure [mm Hg] 75.1 ± 3.6 75.8 ± 3.3 75.3 ± 3.7 78.1 ± 2.0
Fasting serum triglycerides [mg/dL] 167 ± 7.8 166.0 ± 11.2 172.9 ± 10.9 171.6 ± 9.1
High-density lipoprotein cholesterol 52.9 ± 3.1 51.9 ± 4.3 52.1 ± 3.3 49.9 ± 3.2
Fasting serum glucose [mg/dL] 318.5 ± 35.8 306.6 ± 63.4 311.0 ± 31.4 326. ± 28.8
Glycated haemoglobin (%) 9.6 ± 1.1 9.5 ± 1.2 9.0 ± 1.0 9.0 ± 0.8
High-sensitivity C-reactive protein [mg/L] 5.8 ± 0.9 5.7 ± 0.7 5.7 ± 1.1 5.9 ± 1.1
Neopterin [nmol/L] 12.84 ± 1.3 12.5 ± 1.4 12.7 ± 1.0 12.0 ± 1.4
The results are expressed as mean ± standard deviation (SD). No significant difference between different groups of diabetic foot syndrome grading
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patients (18.6 ± 2.1 nmol/L vs. 12.6 ± 1.3 nmol/L). 
The results of this study showed that the alterations in 
serum levels of neopterin were independently related 
to cardiometabolic risk factors and that these relations 
differed depending on the type of diabetes (Tab. 4). In 
T1D, a significant positive correlation between the se-
rum levels of neopterin and diastolic blood pressure was 
observed, while in T2D a significant positive correlation 
was found between fasting serum triglyceride levels 
and neopterin levels (Tab. 4). Moreover, the changes 
in the serum neopterin levels were not related to the 
inflammation. The results of this study showed that 
serum levels of neopterin were insignificantly correlated 
with hs-CRP in T1D and T2D (Fig. 1).
Discussion
The results of this study show that the serum levels 
of hs-CRP and neopterin are significantly higher in T2D 
compared with T1D in patients presented with DFS. The 
cardiometabolic risk factors are associated with DFS, 
but their levels do not show significant differences 
between the grades of DFS in T1D and T2D. There were 
significantly fewer patients with a history of lower 
extremity amputation in T1D group compared with 
T2D group, while the frequency of high-grade wound 
classification (assessed at the time of the study entry), 
although lower in T1D patient, was only insignificantly 
different. The results of this study show that the DFS 
may develop in both T1D and T2D when cardiometa-
Table 3. Cardiometabolic risk factors, inflammatory marker and neopterin levels according to the grading of diabetic 
foot syndrome in Group III patients
Parameters Grading of diabetic foot syndrome
Grade 2 
(n = 13)
Grade 3 
(n = 24)
Grade 4 
(n = 22)
Grade 5 
(n = 11)
Body mass index [kg/m2] 35.3 ± 2.3 35.75 ± 3.26 37.94 ± 3.7 35.88 ± 2.98
Waist circumference (cm) 94.8 ± 5.0 97.2 ± 7.0 98.4 ± 9.6 96.4 ± 8.2
Systolic blood pressure [mm Hg] 147.2 ± 7.0 147.3 ± 4.8 150.6 ± 3.6 151.2 ± 3.0
Diastolic blood pressure [mm Hg] 89.1 ± 6.6 89.4 ± 4.6 91.1 ± 2.8 90.6 ± 6.0
Fasting serum triglycerides [mg/dL] 198.7 ± 18.3 196.4 ± 17.4 196.8 ± 16.2 207.1 ± 20.4
High-density lipoprotein cholesterol [mg/dL] 45.8 ± 2.8 46.3 ± 2.6 45.9 ± 2.1 46.3 ± 3.1
Fasting serum glucose [mg/dL] 223.3 ± 21.0 225.0 ± 25.4 220.2 ± 22.7 223.8 ± 16.9
Glycated haemoglobin (%) 8.0 ± 0.96 7.7 ± 0.7 7.7 ± 0.6 7.7 ± 0.8
High-sensitivity C-reactive protein [mg/L] 12.0 ± 1.7 13.17 ± 2.66 12.48 ± 3.1 11.6 ± 2.0
Neopterin [nmol/L] 19.04 ± 2.02 18.11 ± 2.18 18.47 ± 1.67 19.17 ± 2.8
The results are expressed as mean ± SD. No significant difference between different groups of diabetic foot syndrome grading
Table 4. Correlations between serum levels of neopterin [nmol/L] and cardiometabolic risk factors and the inflammatory 
marker
Independent risk factors T1D T2D
Correlation factor (r) Probability Correlation factor (r) Probability
Duration of diabetes –0.118 0.337 +0.042 0.733
Duration of DFS +0.019 0.877 –0.123 0.317
Body mass index [kg/m2] +0.082 0.506 +0.170 0.165
Waist circumference [cm] –0.128 0.298 +0.102 0.407
Systolic blood pressure [mm Hg] +0.072 0.559 +0.135 0.272
Diastolic blood pressure [mm Hg] +0.261 0.031* +0.042 0.733
Fasting serum triglycerides [mg/dL] +0.219 0.072 +0.248 0.041*
High-density lipoprotein cholesterol [mg/dL] +0.024 0.845 –0.039 0.752
Fasting serum glucose [mg/dL] –0.038 0.758 +0.167 0.173
HbA1c (%) –0.051 0.679 –0.012 0.922
hs-CRP [mg/L] +0.189 0.124 +0.204 0.093
The results are expressed as correlation factor (r) and the corresponding p value
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bolic risk factors are present, regardless the fact that 
the prevalence of the DFS among T1D patients is lower 
than among those with T2D [14]. Hypertriglyceridemia 
(≥ 150 mg/dL) was associated with DFS in both T1D and 
T2D patients, but the overall mean levels of fasting se-
rum triglycerides in Group II patients were significantly 
lower than in Group III patients (168.5 ± 10.1mg/dL 
vs. 198.6 ± 17.7 mg/dL, p < 0.001). These results are 
in agreement with other studies which reported that 
dyslipidaemia is a risk factor of DFS [6, 15]. The levels 
of fasting serum triglycerides in each group had no 
significant relation to the Wagner-Meggitt classification 
of DFS. High blood pressure was observed significantly 
more frequently in Group III compared with Group II 
(systolic 148.9 ± 5.0 mm Hg vs. 131.2 ± 3.5 mm Hg 
and diastolic 90.0 ± 4.6 vs. 75.8 ± 3.4 mm Hg). These 
findings are compatible with other studies reporting 
the prevalence of hypertension among diabetic patients 
with foot ulceration of 57.1% [16]. Again, blood pres-
sure values were not related to the severity of DFS. All 
the patients in Group II and Group III were obese and 
this observation not only supported the hypothesis on 
the role of adipovascular axis in T2D, but also extended 
it to T1D [17]. The measurements of diabetic control, 
i.e. fasting serum glucose and glycated haemoglobin, 
were worse in T1D compared with T2D patients, but 
did not show significant variations in respect to the 
severity of DFS [18]. The results of this study clearly 
confirm previous reports that significantly higher 
levels of hs-CRP and neopterin were observed in T2D 
complicated with foot ulcers [19, 21]. Higher serum 
levels of neopterin among T2D compared with T1D 
patients indicates activation of cell-mediated immune 
response and increase in reactive oxygen species [22, 
23]. Previous studies showed that neopterin levels were 
influenced by proinflammatory and anti-inflammatory 
cytokines and this explains the insignificant correlation 
between serum neopterin and hs-CRP levels observed 
in this study [24]. Two important findings of our study 
should be highlighted: first one is the lack of relation-
ship between serum neopterin levels and inflammation; 
and the second finding is the observation that serum 
neopterin correlation with metabolic risk factors de-
pends on the type of diabetes. A significant correlation 
between blood pressure and serum levels of neopterin 
in T1D patient is a new finding and confirms previous 
studies that showed increased serum neopterin levels 
in preeclampsia [25]. The other significant positive 
correlation of neopterin was with the serum levels of 
triglyceride in T2D, which confirmed the results of previ-
ous studies [26]. One of the limitations of our study is 
small sample size, which precluded statistical analysis 
of serum neopterin levels and their correlations with 
cardiometabolic risk factors in respect to the grading 
and severity of cardiometabolic risk factors.
There is no doubt that dyslipidaemia, obesity 
and high blood pressure are contributing factors that 
accelerate the development of micro- and macrovas-
cular complications in diabetes, including DFS. This 
study accepted the hypothesis that cardiometabolic 
risk factors play a role in the development of diabetic 
complications.
Conclusions
We conclude that cardiometabolic risk factors are 
associated with DFS in T1D and T2D and that their levels 
are not related to DFS severity assessed according to 
the Wagner-Meggitt classification. Serum levels of neo-
Figure 1. Correlations between serum levels of high-sensitivity C-reactive protein and serum neopterin levels in patients with 
diabetic foot syndrome
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pterin are significantly increased in DFS and are higher 
inT2D compared with T1D patients. Determination of 
serum neopterin level can serve as a cardiometabolic 
risk factor rather than an inflammatory marker and the 
type of diabetes should be considered in the interpreta-
tion of the changes in serum neopterin levels. 
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